1. Home
  2. AVBP

as 05-20-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

Founded: 2021 Country:
United States
United States
Employees: N/A City: NEWTOWN SQUARE
Market Cap: 577.8M IPO Year: 2024
Target Price: $29.25 AVG Volume (30 days): 170.8K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.23 EPS Growth: N/A
52 Week Low/High: $14.35 - $25.95 Next Earning Date: 05-08-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 83.33%

Share on Social Networks:

Stock Insider Trading Activity of ARRIVENT BIOPHARMA INC (AVBP)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
GORDON CARL L AVBP Director10% Owner Jan 30 '24 Buy $18.00 222,222 $3,999,996.00 1,513,664 SEC Form 4
GORDON CARL L AVBP Director10% Owner Jan 30 '24 Buy $18.00 222,222 $3,999,996.00 1,513,664 SEC Form 4
ORBIMED ADVISORS LLC AVBP Director10% Owner Jan 30 '24 Buy $18.00 222,222 $3,999,996.00 1,513,664 SEC Form 4
ORBIMED ADVISORS LLC AVBP Director10% Owner Jan 30 '24 Buy $18.00 222,222 $3,999,996.00 1,513,664 SEC Form 4